Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer
A growing body of literature links events associated with the progression and severity of immunity and inflammatory disease with the composition of the tissue extracellular matrix as defined by the matrisome. One protein in the matrisome that is common to many inflammatory diseases is the large prot...
Main Authors: | Priyanka Hirani, Valentine Gauthier, Carys E. Allen, Thomas N. Wight, Oliver M. T. Pearce |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.712807/full |
Similar Items
-
Versican expression in canine carcinomas in benign mixed tumours: is there an association with clinical pathological factors, invasion and overall survival?
by: Damasceno Karine A, et al.
Published: (2012-10-01) -
Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation
by: Thomas N. Wight, et al.
Published: (2020-03-01) -
Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts
by: Kamila Wojas-Krawczyk, et al.
Published: (2021-06-01) -
Tumour devascularisation as a potential immunotherapeutic strategy
by: Tomas Buchler, et al.
Published: (2019-01-01) -
Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response
by: Shuhui Cheng, et al.
Published: (2020-09-01)